HRP20120681T1 - Stabilni kristal 4-oksokinolinskog spoja - Google Patents

Stabilni kristal 4-oksokinolinskog spoja Download PDF

Info

Publication number
HRP20120681T1
HRP20120681T1 HRP20120681TT HRP20120681T HRP20120681T1 HR P20120681 T1 HRP20120681 T1 HR P20120681T1 HR P20120681T T HRP20120681T T HR P20120681TT HR P20120681 T HRP20120681 T HR P20120681T HR P20120681 T1 HRP20120681 T1 HR P20120681T1
Authority
HR
Croatia
Prior art keywords
crystal
crystal according
ray powder
mixed
dihydroquinoline
Prior art date
Application number
HRP20120681TT
Other languages
English (en)
Croatian (hr)
Inventor
Satoh Motohide
Motomura Takahisa
Matsuda Takashi
Kondo Kentaro
Ando Koji
Matsuda Koji
Miyake Shuji
Uehara Hideto
Original Assignee
Japan Tobacco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120681(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco filed Critical Japan Tobacco
Publication of HRP20120681T1 publication Critical patent/HRP20120681T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
HRP20120681TT 2004-05-20 2005-05-19 Stabilni kristal 4-oksokinolinskog spoja HRP20120681T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004150979 2004-05-20
PCT/JP2005/009604 WO2005113508A1 (fr) 2004-05-20 2005-05-19 Cristal stable de compose 4-oxoquinoline

Publications (1)

Publication Number Publication Date
HRP20120681T1 true HRP20120681T1 (hr) 2012-09-30

Family

ID=35079161

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20231588TT HRP20231588T3 (hr) 2004-05-20 2005-05-19 Kombinacija koja sadrži stabilni kristal 4-oksokinolinskog spoja
HRP20120681TT HRP20120681T1 (hr) 2004-05-20 2005-05-19 Stabilni kristal 4-oksokinolinskog spoja

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20231588TT HRP20231588T3 (hr) 2004-05-20 2005-05-19 Kombinacija koja sadrži stabilni kristal 4-oksokinolinskog spoja

Country Status (33)

Country Link
US (7) US7635704B2 (fr)
EP (4) EP1636190B1 (fr)
JP (1) JP3754064B2 (fr)
KR (1) KR20080064909A (fr)
CN (1) CN1956961B (fr)
AR (2) AR049280A1 (fr)
AU (1) AU2005245296B2 (fr)
BE (1) BE2024C511I2 (fr)
BR (1) BRPI0510114B8 (fr)
CA (1) CA2566922C (fr)
CY (4) CY1113010T1 (fr)
DK (2) DK1636190T3 (fr)
ES (2) ES2388441T3 (fr)
FI (2) FI3281939T3 (fr)
FR (1) FR23C1040I1 (fr)
HR (2) HRP20231588T3 (fr)
HU (2) HUE064615T2 (fr)
IL (1) IL179250A0 (fr)
LT (2) LT3281939T (fr)
LU (1) LUC00334I2 (fr)
MX (1) MXPA06013405A (fr)
MY (1) MY134672A (fr)
NO (8) NO339223B1 (fr)
NZ (1) NZ551839A (fr)
PE (2) PE20120361A1 (fr)
PL (2) PL1636190T3 (fr)
PT (2) PT3281939T (fr)
RS (2) RS64845B1 (fr)
RU (1) RU2330845C1 (fr)
SI (2) SI1636190T1 (fr)
TW (1) TWI329015B (fr)
WO (1) WO2005113508A1 (fr)
ZA (1) ZA200610647B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891227B2 (en) 2002-03-20 2005-05-10 International Business Machines Corporation Self-aligned nanotube field effect transistor and method of fabricating same
KR100665919B1 (ko) * 2002-11-20 2007-03-08 니뽄 다바코 산교 가부시키가이샤 4-옥소퀴놀린 화합물 및 ｈｉｖ 인테그라제 저해제로서의그의 용도
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2007063869A1 (fr) * 2005-11-30 2007-06-07 Japan Tobacco Inc. Procede de fabrication d’un compose de quinolone de grande purete
EA201201496A1 (ru) 2005-12-30 2013-07-30 Джилид Сайэнс, Инк. Способ ингибирования интегразы вич, способ улучшения фармакокинетики 6-(3-хлор-2-фторбензил)-1-[(2s)-1-гидрокси-3-метилбутан-2-ил]-7-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновой кислоты (варианты), набор, фармацевтическая композиция (варианты) и антиретровирусный агент (варианты)
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
WO2007089030A1 (fr) * 2006-02-01 2007-08-09 Japan Tobacco Inc. Utilisation d'acide 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-méthylbutan-2-yl]-7-méthoxy-4-oxo-1,4-dihydroquinoléine-3-carboxylique ou d'un de ses sels pour traiter une infection rétrovirale
WO2007092802A1 (fr) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Méthode pour traiter une infection au vih par co-administration de tipranavir et de gs 9137
IN2014CN00532A (fr) 2006-03-06 2015-04-03 Japan Tobacco Inc
WO2007102512A1 (fr) 2006-03-06 2007-09-13 Japan Tobacco Inc. Procede de production d'un compose 4-oxoquinoline
AU2007275860C1 (en) 2006-07-07 2014-06-12 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
SG174787A1 (en) 2006-09-12 2011-10-28 Gilead Sciences Inc Process and intermediates for preparing integrase inhibitors
HUE029842T2 (en) 2007-02-23 2017-04-28 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
TW200914011A (en) * 2007-06-29 2009-04-01 Gilead Sciences Inc Therapeutic compositions and methods
WO2009006203A1 (fr) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Compositions thérapeutiques et leur utilisation
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
PT2296633E (pt) 2008-05-02 2015-12-04 Gilead Sciences Inc A utilização de partículas de portador sólido para melhorar a processabilidade de um agente farmacêutico
JP5611242B2 (ja) 2009-02-06 2014-10-22 ギリアード サイエンシーズ， インコーポレイテッド 併用治療のための錠剤
WO2010137032A2 (fr) * 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Nouvelles formes polymorphes d'elvitégravir et sels pharmaceutiquement acceptables de celui-ci
WO2011004389A2 (fr) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd Procédé amélioré pour la préparation d'elvitegravir
CN102212032B (zh) * 2011-04-20 2013-07-31 复旦大学 一种5-羟基喹诺酮类衍生物及其制备方法和用途
KR101663436B1 (ko) 2012-07-06 2016-10-06 제넨테크, 인크. N-치환된 벤즈아미드 및 이의 사용 방법
BR112015002275A2 (pt) 2012-08-03 2017-07-04 Gilead Sciences Inc processos e intermediários para a preparação de inibidores da integrase
CN103819402B (zh) * 2012-11-17 2016-03-30 上海迪赛诺化学制药有限公司 埃替拉韦中间体及其制备方法和应用
CN103864682B (zh) * 2012-12-18 2016-12-28 上海迪赛诺化学制药有限公司 一种制备iii型埃替拉韦晶体的方法
PL3608325T3 (pl) 2012-12-21 2022-11-07 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonu i ich zastosowanie farmaceutyczne
HUE037347T2 (hu) 2013-07-12 2018-08-28 Gilead Sciences Inc Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
NO2865735T3 (fr) 2013-07-12 2018-07-21
CN105315203A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种v型埃替拉韦晶体及其制备方法
NO2717902T3 (fr) 2014-06-20 2018-06-23
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
ES2837383T3 (es) 2015-04-02 2021-06-30 Gilead Sciences Inc Compuestos de carbamoilpiridonas policíclicos y su utilización farmacéutica
CN106008195B (zh) * 2016-05-19 2018-08-03 绍兴文理学院 一种2，4-二氟-5-碘苯甲酸的制备方法
EP3984536B1 (fr) * 2020-10-19 2025-06-25 Centre national de la recherche scientifique Inhibition de la réplication du vih-1 par des composés dirigés contre une nouvelle cible du cycle viral

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS567162B1 (fr) 1970-09-14 1981-02-16
JPS4826772A (fr) 1971-08-11 1973-04-09
JPS6450979A (en) 1987-08-21 1989-02-27 Hitachi Shipbuilding Eng Co Method for discriminating whistle sound
JPH0651229B2 (ja) 1989-07-31 1994-07-06 新日本製鐵株式会社 プラズマアーク溶接方法および装置
IL100555A (en) * 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
NO304832B1 (no) * 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
RU2140919C1 (ru) * 1994-07-18 1999-11-10 Убе Индастриз Лтд. Производные 8-трифторметилхинолинкарбоновой кислоты, фармацевтическая композиция и способ ингибирования вируса иммунодефицита
JPH0826772A (ja) 1994-07-22 1996-01-30 Sony Corp 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法
ATE211471T1 (de) 1996-04-12 2002-01-15 Us Gov Health & Human Serv Acridonderivate als antineoplastische-und antiretrovirale mittel
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
GB9721964D0 (en) * 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
PE20011349A1 (es) 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6841558B2 (en) 2000-10-12 2005-01-11 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as HIV intergrase inhibitors
US20050010048A1 (en) 2000-10-12 2005-01-13 Linghang Zhuang Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors
CN1659143A (zh) 2001-03-01 2005-08-24 盐野义制药株式会社 具有hiv整合酶抑制活性的含氮杂芳基化合物
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
FR2827600A1 (fr) 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
RU2206564C1 (ru) * 2002-03-07 2003-06-20 Общество с ограниченной ответственностью "Поливит" Способ получения этилового эфира 6-фтор-7-хлор-1,4-дигидро-4-оксо-3-хинолинкарбоновой кислоты
JP4035765B2 (ja) 2002-10-31 2008-01-23 横河電機株式会社 フーリエ変換型赤外線分光計
KR100665919B1 (ko) * 2002-11-20 2007-03-08 니뽄 다바코 산교 가부시키가이샤 4-옥소퀴놀린 화합물 및 ｈｉｖ 인테그라제 저해제로서의그의 용도
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US7531554B2 (en) * 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
US8633219B2 (en) * 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy

Also Published As

Publication number Publication date
EP1636190B1 (fr) 2012-06-27
TW200600097A (en) 2006-01-01
NO20161297A1 (no) 2007-02-07
US20060030710A1 (en) 2006-02-09
JP3754064B2 (ja) 2006-03-08
US7635704B2 (en) 2009-12-22
PT1636190E (pt) 2012-08-20
FI3281939T3 (fi) 2023-10-23
FR23C1040I1 (fr) 2023-12-29
EP3281939A1 (fr) 2018-02-14
BE2024C511I2 (fr) 2024-10-08
EP4299563A3 (fr) 2024-02-28
CA2566922C (fr) 2011-01-11
NO20190051A1 (no) 2007-02-07
MXPA06013405A (es) 2007-03-01
AR096100A2 (es) 2015-12-09
NO347902B1 (no) 2024-05-06
LTPA2024001I1 (fr) 2024-04-10
RS52375B (sr) 2012-12-31
DK3281939T3 (da) 2024-01-22
SI1636190T1 (sl) 2012-09-28
ES2388441T3 (es) 2012-10-15
NO20220690A1 (no) 2007-02-07
BRPI0510114B1 (pt) 2020-09-15
NO2024034I1 (no) 2024-07-15
CY2015009I1 (el) 2024-09-20
US20180029989A1 (en) 2018-02-01
CY1126560T1 (el) 2024-09-20
AR049280A1 (es) 2006-07-12
NO20240384A1 (no) 2007-02-07
FIC20240008I1 (fi) 2024-03-20
US8981103B2 (en) 2015-03-17
EP2514746A1 (fr) 2012-10-24
IL179250A0 (en) 2007-03-08
RU2330845C1 (ru) 2008-08-10
KR20080064909A (ko) 2008-07-09
PE20060358A1 (es) 2006-05-12
NO20230913A1 (no) 2007-02-07
NO20200873A1 (no) 2007-02-07
PL1636190T3 (pl) 2012-10-31
BRPI0510114B8 (pt) 2021-05-25
DK1636190T3 (da) 2012-09-24
JP2006001927A (ja) 2006-01-05
PL3281939T3 (pl) 2024-03-18
HK1083341A1 (en) 2006-06-30
HUE064615T2 (hu) 2024-04-28
ZA200610647B (en) 2008-06-25
CY2015009I2 (el) 2024-09-20
CY2024008I1 (el) 2024-09-20
US20250091995A1 (en) 2025-03-20
US20190185433A1 (en) 2019-06-20
CN1956961A (zh) 2007-05-02
HRP20231588T3 (hr) 2024-03-15
AU2005245296A1 (en) 2005-12-01
NO339223B1 (no) 2016-11-21
HUS2400006I1 (hu) 2024-04-28
US20220235009A1 (en) 2022-07-28
EP4299563A2 (fr) 2024-01-03
LT3281939T (lt) 2023-11-27
US20150361044A1 (en) 2015-12-17
SI3281939T1 (sl) 2024-02-29
AU2005245296B2 (en) 2010-08-12
PT3281939T (pt) 2023-11-22
BRPI0510114A (pt) 2007-09-25
NO20065790L (no) 2007-02-07
CY1113010T1 (el) 2016-04-13
TWI329015B (en) 2010-08-21
LTC3281939I2 (fr) 2025-04-25
NZ551839A (en) 2009-11-27
LUC00334I2 (fr) 2024-07-01
WO2005113508A1 (fr) 2005-12-01
EP3281939B1 (fr) 2023-10-18
PE20120361A1 (es) 2012-05-03
MY134672A (en) 2007-12-31
ES2960824T3 (es) 2024-03-06
CY2024008I2 (el) 2024-09-20
US20100204271A1 (en) 2010-08-12
CN1956961B (zh) 2010-05-26
CA2566922A1 (fr) 2005-12-01
RS64845B1 (sr) 2023-12-29
EP1636190A1 (fr) 2006-03-22

Similar Documents

Publication Publication Date Title
HRP20120681T1 (hr) Stabilni kristal 4-oksokinolinskog spoja
CA2757418C (fr) Formulations pharmaceutiques contenant des derives de nitrocatechol et procedes pour les preparer
CA2391953A1 (fr) Derives d'acide nervonique, preparation et utilisation associees
DK1373202T3 (da) Fremstilling af ikke-krystallinsk atorvastatincalcium
SI9620040B (sl) Postopek in kristalne oblike 2-metil-tieno-benzodiazepina
CA2431068A1 (fr) Formes cristallines d'atorvastatine
CA2378382A1 (fr) Amides d'acide carboxylique, compositions pharmaceutiques contenant ces composes, leur utilisation et leur preparation
CA2446944A1 (fr) Derives d'acides amines anti-inflammatoires et immunomodulateurs, leur preparation et leur utilisation
ES2179318T3 (es) Derivados de acido cinamico y su uso como antagonistas de integrina.
HRP20100455T1 (hr) Maleatne soli derivata kinazolina korisne kao antiangiogeno sredstvo
CA2453917A1 (fr) Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif
HRP20120700T1 (hr) SOLI SPOJEVA INHIBITORA HIV-a
HUP9701090A2 (hu) Mikropórusos kristályos anyag, eljárás ennek előállítására és detergens készítményekben való alkalmazása
HRP20121074T1 (hr) Derivati kinolina i njihovi farmaceutski sastavi
HRP20110712T1 (hr) Novi postupak za dobivanje kristalnog oblika agomelatina
CA2370376A1 (fr) Cristaux de mirtazapine anhydres et leur procede de fabrication
CA2128601A1 (fr) Derives de l'acide quinolonecarboxylique sous forme d'hydrate cristallin
EP1310485A4 (fr) Derives du pyrrole
MY134325A (en) Quinoline derivatives
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
HRP20100217T1 (hr) POLIMORFI tert-BUTILNOG ESTERA ATORVASTATINA I NJIHOVA UPOTREBA KAO MEĐUPRODUKATA U DOBIVANJU ATORVASTATINA
HU210154B (en) Process for producing new famotidin-salts and pharmaceutical compositions of gastro-acid-secretion-inhibiting and gastro-citoprotective activity, containing them
IE46327B1 (en) Carbocylic fused thiophen-2-oxaminic acid derivatives
CN106187970A (zh) 新的α-葡萄糖苷酶抑制剂
ATE239699T1 (de) Hydroxyphenylsulfanylbenzoesäure- und - arylessigsäure-derivate